A fellow of Royal Society and one of the world’s highly cited respiratory researchers who has published over 1,000 peer-reviewed papers on asthma, COPD and related topics, and a senior research investigator at the National Heart and Lung Institute, Imperial College London.

A veteran in the development of antiviral therapies and Distinguished Professor of Pediatrics at the University of Alabama at Birmingham, and a board member of Gilead Science; He is a member of the COVID-19 Vaccine Data and Safety Monitoring Board established by the National Institute of Allergy and Infectious Disease in the U.S.

An expert in pulmonary pharmacology with over 18 years of experience at the FDA, where she served as primary clinical reviewer, clinical team leader, cross-discipline team leader (CDTL), and, most recently, deputy division director overseeing the treatment development for lung diseases, including IPF and COPD.

A drug safety pharmacology expert with over 18 years of industry experience and a member of the Division of Cardiovascular Medicine, Department of Clinical Science at the Karolinska Institute in Sweden. He is the chief scientific officer of eResearchTechnology (ERT), a global leading data and technology company specializing in clinical trial services.

Michel has over 30 years of leadership and management experience in top pharmaceutical and biotech companies, covering both established and emerging markets globally. He has been CEO and board member of Biogen, Chairman and President of MSD China, and held several leadership roles in MSD’s operations in Europe. Michel has successful track records of turning around businesses and achieving strong company performance.